Medical oncologist and lung cancer expert Dr. Naomi Fujioka provides an overview of how
lung cancers with
KRAS mutations are
treated. She discusses the use of KRAS inhibitors sotorasib and adagrasib that target the
KRAS G12C mutation. She also discusses ongoing clinical trials researching how to combine KRAS inhibitors with other treatments, using KRAS inhibitors earlier in lung cancer treatment, and research on therapies targeting
KRAS G12D.
-
Share with family and friends:
Click here to take our SURVEY
Your feedback is important to us! We will use your feedback to develop future areas of content about lung cancer which will help other patients, caregivers and families.